BridgeBio Oncology Therapeutics (BBOT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- —
- Estimate
- -$0.54
- Surprise
- —
- Score today
- 4.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
Coverage in the report window
- BridgeBio Oncology Q2 EPS $(705.20) Misses $(0.57) Estimate — benzinga, 2026-08-11
Where TrendMatrix's rating stands now
TrendMatrix currently rates BBOT Hold at 4.5/10; no pre/post engine snapshot brackets this report.
1 of the last 3 quarters beat the estimate. Next scheduled report: 2026-11-11.
What argues against it
- DATA_ISSUE: analyst_target_implausible (raw $24.73 vs price $4.76 — ratio 5.2×). Rejected, falling back to technical TP.
- Market cap $391M below $400M minimum
- Momentum score 2.3/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $4.70
- Price target
- $9.58
- Stop
- $4.57
- Upside to target
- +103.8%
Risk check: RSI 7 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
BBOT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $391.3M
- P/E (fwd)
- -1.8
- 52-week range
- $4.72–$14.87
- Off 52-week high
- 68.4%
- RSI (14)
- 7
- Volume vs avg
- 1.45×
- Score today
- 4.5/10